Celldex Therapeutics (NASDAQ:CLDX) Price Target Lowered to $61.00 at Cantor Fitzgerald

Celldex Therapeutics (NASDAQ:CLDX) had its target price lowered by equities researchers at Cantor Fitzgerald from $67.00 to $61.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 71.06% from the stock’s current price.

A number of other analysts also recently issued reports on the company. UBS Group lifted their target price on Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. HC Wainwright reiterated a “buy” rating and issued a $42.00 target price on shares of Celldex Therapeutics in a research note on Monday, June 15th. Guggenheim increased their price target on Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday. Barclays lifted their price objective on shares of Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Finally, Wells Fargo & Company increased their price objective on shares of Celldex Therapeutics from $38.00 to $54.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $54.33.

Celldex Therapeutics Stock Up 0.7%

Shares of NASDAQ:CLDX opened at $35.66 on Wednesday. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of -8.37 and a beta of 0.90. Celldex Therapeutics has a 12 month low of $19.72 and a 12 month high of $40.30. The company’s fifty day simple moving average is $33.46 and its 200 day simple moving average is $30.53.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.80 million. Research analysts expect that Celldex Therapeutics will post -4.36 earnings per share for the current fiscal year.

Institutional Trading of Celldex Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP boosted its position in shares of Celldex Therapeutics by 39.3% during the 4th quarter. Wellington Management Group LLP now owns 8,079,608 shares of the biopharmaceutical company’s stock worth $219,442,000 after acquiring an additional 2,279,605 shares in the last quarter. Vanguard Group Inc. raised its stake in Celldex Therapeutics by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 4,027,407 shares of the biopharmaceutical company’s stock worth $109,384,000 after acquiring an additional 72,817 shares in the last quarter. Bellevue Group AG grew its holdings in shares of Celldex Therapeutics by 7.6% during the 3rd quarter. Bellevue Group AG now owns 3,557,669 shares of the biopharmaceutical company’s stock valued at $92,037,000 after purchasing an additional 250,100 shares during the last quarter. Commodore Capital LP increased its holdings in shares of Celldex Therapeutics by 7.8% during the second quarter. Commodore Capital LP now owns 3,450,000 shares of the biopharmaceutical company’s stock worth $70,208,000 after buying an additional 250,000 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Celldex Therapeutics by 19.5% during the 4th quarter. State Street Corp now owns 3,397,713 shares of the biopharmaceutical company’s stock valued at $92,282,000 after acquiring an additional 555,579 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.